Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.31 |
| ▸ | NOS1 | P29475 | 2/20 | 0.31 |
| ▸ | NOS2 | P35228 | 2/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25606946 | 0.79 | ALOX15 (0.31) | ALOX15ALOX12 | |
| SCHEMBL12848426 | 0.73 | NOS3 (0.35) | NOS3NOS1NOS2 | |
| SCHEMBL21736983 | 0.73 | GRIN2D (0.34) | NOS3NOS1NOS2ALOX15 | |
| SCHEMBL25606877 | 0.72 | TSHR (0.34) | — | |
| SCHEMBL13636034 | 0.71 | NOS3 (0.34) | NOS3NOS1NOS2 | |
| SCHEMBL24838164 | 0.71 | NOS3 (0.31) | NOS3NOS1NOS2 | |
| SCHEMBL22185962 | 0.70 | CYP11B1 (0.35) | NOS3NOS1NOS2 | |
| SCHEMBL25631745 | 0.70 | NOS3 (0.42) | NOS3NOS1NOS2 | |
| SCHEMBL23231054 | 0.69 | NOS3 (0.41) | NOS3NOS1NOS2ALOX15ALOX12 | |
| SCHEMBL24759678 | 0.68 | NOS3 (0.39) | NOS3NOS1NOS2ALOX15ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11680056-B2 | MK2 inhibitors and uses thereof | XINTHERA, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| WO-2023278402-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11680056-B2 | MK2 inhibitors and uses thereof | MKNK2, ENPP2, MAPKAPK2 | NOS3 3656/4885NOS1 3327/4885NOS2 1407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.